Catalent Inc (NYSE:CTLT) Position Lessened by Louisiana State Employees Retirement System
Louisiana State Employees Retirement System decreased its stake in Catalent Inc (NYSE:CTLT) by 4.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 37,200 shares of the company’s stock after selling 1,800 shares during the period. Louisiana State Employees Retirement System’s holdings in Catalent were worth $1,988,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Nordea Investment Management AB raised its holdings in Catalent by 1.3% during the first quarter. Nordea Investment Management AB now owns 109,340 shares of the company’s stock valued at $4,438,000 after buying an additional 1,350 shares in the last quarter. Zions Bancorporation N.A. bought a new position in shares of Catalent in the first quarter worth about $61,000. Westfield Capital Management Co. LP increased its stake in shares of Catalent by 29.3% in the first quarter. Westfield Capital Management Co. LP now owns 448,946 shares of the company’s stock worth $18,223,000 after purchasing an additional 101,645 shares during the period. Lazard Asset Management LLC increased its stake in shares of Catalent by 149.5% in the first quarter. Lazard Asset Management LLC now owns 741,200 shares of the company’s stock worth $30,085,000 after purchasing an additional 444,120 shares during the period. Finally, Swiss National Bank increased its stake in shares of Catalent by 3.4% in the first quarter. Swiss National Bank now owns 264,970 shares of the company’s stock worth $10,755,000 after purchasing an additional 8,800 shares during the period. 96.85% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts have weighed in on CTLT shares. Morgan Stanley downgraded GasLog Partners LP Unit from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $23.00 to $18.00 in a report on Tuesday, April 16th. Zacks Investment Research downgraded Eisai from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Jefferies Financial Group reissued a “buy” rating on shares of Linde in a report on Friday, June 21st. ValuEngine raised ZTE CORP/ADR from a “hold” rating to a “buy” rating in a report on Monday, April 15th. Finally, UBS Group reissued a “hold” rating and issued a $130.00 target price on shares of Continental in a report on Tuesday. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $55.14.
CTLT stock opened at $57.26 on Friday. The company has a quick ratio of 1.71, a current ratio of 2.18 and a debt-to-equity ratio of 1.31. The stock has a 50 day moving average of $53.03. Catalent Inc has a fifty-two week low of $29.23 and a fifty-two week high of $57.45. The company has a market cap of $8.34 billion, a PE ratio of 36.01, a PEG ratio of 2.77 and a beta of 1.64.
Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.07. Catalent had a net margin of 6.01% and a return on equity of 16.78%. The firm had revenue of $617.50 million during the quarter, compared to analysts’ expectations of $644.88 million. During the same quarter in the previous year, the company posted $0.41 EPS. Catalent’s revenue was down 1.7% on a year-over-year basis. On average, equities research analysts anticipate that Catalent Inc will post 1.71 earnings per share for the current year.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Article: What does a dividend yield signify to investors?
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.